Dr Ana Oaknin speaks to ecancer about the results of the randomised phase III BEATcc academic trial.

This study showed that adding immune checkpoint inhibitor atezolizumab to standard of care with bevacizumab and chemotherapy significantly improves progression-free survival and overall survival in patients with metastatic or recurrent cervical cancer who are not candidates for curative-intent surgery and/or radiotherapy.

Dr Oakinin says that this study is the first to add a PD-L1 inhibitor to standard of care with bevacizumab plus platinum-based doublet chemotherapy in this setting.

Read the full story here.